Kevin D’Amour

Company: Stemson Therapeutics LLC

Job title: Chief Scientific Officer

Seminars:

Directing Differentiation to High Purity Cell Populations Appropriate for Cellular Therapy 11:00 am

Examining current and novel technologies to successfully characterize undifferentiated cells to reduce product contamination Diving beyond karyotypic screening to drive reliable assessment of genomic integrity Evaluating the role maturity plays in differentiation to understand why iPSCs do not always fully differentiate into their potentialRead more

day: Day Two Track AM

iPSC Leaders Panel: Highlighting the Next Steps for the Future of iPSC-Derived Cell Therapies 8:50 am

Reflecting on how far the field has come to reaffirm iPSCs as the cornerstone of regenerative cell therapies Understanding the prospects of iPSC and laying out the trajectory to unite industry experts to propel regulatory approval Discussing the progression of, and clinical readiness for, iPSC technologies to identify areas in need of greater attentionRead more

day: Conference Day One